ArticleJournal of molecular histology2025
Therapeutic effects of Scutellaria baicalensis total flavonoids on metabolic syndrome in rats via modulation of PPARα and PPARγ signaling.
Article in Journal of molecular histology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The aim of this study is to evaluate the therapeutic effects of Scutellaria baicalensis total flavonoids (STF) in a rat model of metabolic syndrome (MS), with particular focus on the core regulatory mechanisms contributing to metabolic homeostasis. Additionally, the modulation of peroxisome proliferator-activated receptors (PPARs) by STF was investigated to elucidate its molecular targets and associated features within the pathophysiology of MS. Metabolic syndrome was induced in Sprague Dawley rats through the administration of a high-fat/high-glucose diet combined with streptozotocin (STZ). STF was administered orally during the induction period. Serum levels of triglycerides (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), fasting blood glucose (FBG), and fasting insulin (FINS) were quantified. The homeostatic model assessment of insulin resistance (HOMA-IR) was calculated. Hepatic concentrations of TC and TG were also measured. Histopathological alterations were evaluated using hematoxylin and eosin (HE) staining, while hepatic lipid accumulation was assessed through Oil Red O staining. Hepatic expression levels of PPARα and PPARγ proteins were determined via Western blot analysis. Treatment with STF at doses of 50 and 100 mg·kg⁻¹ significantly reduced serum levels of TC, TG, LDL-C, FBG, FINS, and HOMA-IR, while preventing the decline in HDL-C levels among rats with MS. STF administration also alleviated abnormal liver weight and suppressed hepatic accumulation of TC and TG, accompanied by improvements in histological features. Western blot analysis revealed upregulation of hepatic PPARα and PPARγ protein expression following STF treatment. STF demonstrated the capacity to reduce body weight and improve lipid profiles and insulin resistance in rats with MS. These effects may be associated with the regulation of PPARα and PPARγ protein expression.
Indexed as
Identifiers
40982079What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.